PT  - JOURNAL ARTICLE
AU  - Ogega, Clinton O.
AU  - Skinner, Nicole E.
AU  - Blair, Paul W.
AU  - Park, Han-Sol
AU  - Littlefield, Kirsten
AU  - Ganesan, Abhinaya
AU  - Ladiwala, Pranay
AU  - Antar, Annukka AR
AU  - Ray, Stuart C.
AU  - Betenbaugh, Michael J.
AU  - Pekosz, Andrew
AU  - Klein, Sabra L.
AU  - Manabe, Yukari C.
AU  - Cox, Andrea L.
AU  - Bailey, Justin R.
TI  - Durable SARS-CoV-2 B cell immunity after mild or severe disease
AID  - 10.1101/2020.10.28.20220996
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.10.28.20220996
4099  - http://medrxiv.org/content/early/2020/10/30/2020.10.28.20220996.short
4100  - http://medrxiv.org/content/early/2020/10/30/2020.10.28.20220996.full
AB  - Multiple studies have shown loss of SARS-CoV-2 specific antibodies over time after infection, raising concern that humoral immunity against the virus is not durable. If immunity wanes quickly, millions of people may be at risk for reinfection after recovery from COVID-19. However, memory B cells (MBC) could provide durable humoral immunity even if serum neutralizing antibody titers decline. We performed multi-dimensional flow cytometric analysis of S protein receptor binding domain (S-RBD)-specific MBC in cohorts of ambulatory COVID-19 patients with mild disease, and hospitalized patients with moderate to severe disease, at a median of 54 (39-104) days after onset of symptoms. We detected S-RBD-specific class-switched MBC in 13 out of 14 participants, including 4 of the 5 participants with lowest plasma levels of anti-S-RBD IgG and neutralizing antibodies. Resting MBC (rMBC) made up the largest proportion of S-RBD-specific class-switched MBC in both cohorts. FCRL5, a marker of functional memory when expressed on rMBC, was dramatically upregulated on S-RBD-specific rMBC. These data indicate that most SARS-CoV-2-infected individuals develop S-RBD-specific, class-switched MBC that phenotypically resemble germinal center-derived B cells induced by effective vaccination against other pathogens, providing evidence for durable B cell-mediated immunity against SARS-CoV-2 after recovery from mild or severe COVID-19 disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by the National Institutes of Health grants R01AI127469 and R21AI151353 (to J.R.B.), U54CA260492 (SLK and AC), and in part by the NIH Center of Excellence for Influenza Research and Surveillance (HHSN272201400007C, to AP and SLK).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Johns Hopkins University School of Medicine IRB00248905All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAfter publication, all data referred to in the manuscript is available on request.